Allergan heads to federal court to defend Restasis against early generic rivals

Fierce Pharma ------- In defense of a top seller, Allergan is squaring off against generics companies in Texas federal court, accusing copycat makers of violating its patent protections on blockbuster eye medication Restasis. The trial started Monday at U.S. District Court in Marshall, Texas, where Allergan is challenging Mylan, Teva Pharmaceuticals, Akorn and Inno Pharma, a division of Pfizer. In a note late Monday, Evercore ISI analyst Umer Raffat said the testimony was “incrementally positive” for Allergan on Day 1. To learn more click on the picture below to read the article.